About Us

Who we are

H3 Biomedicine is a leading company in cancer genomics based drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million funding commitment from Eisai plus additional funding for clinical programs. As a clinical-stage biopharmaceutical company, we uniquely leverage our distinct insights from cancer genomics and real-life patient data to advance our projects to clinical proof of concept and beyond. H3 embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company to create a prolific drug discovery engine and partnership platform.

X

Leadership

Terushige Iike, M.B.A.

Chief Executive Officer

Terushige Iike, M.B.A.

Chief Executive Officer

Mr. Terushige Iike is Chief Executive Officer of H3 Biomedicine, a role in which he is responsible for the overall business direction of the company. Mr. Iike also serves as president of the Oncology Business Group at Eisai Co., Ltd., overseeing the global end-to-end activities from discovery research and clinical development to brand commercialization and business development of Eisai’s global oncology business.

Mr. Iike began his career as a project manager in Eisai’s Drug Development Department in 1986. During his career at Eisai, Mr. Iike has held positions of increasing responsibility in both R&D and corporate strategy, including vice president of Corporate Strategy and president of the Japan/Asia Clinical Research of Eisai Product Creation Systems. In October 2014, he was named chief product creation officer, responsible for Eisai’s global research and drug development. He was named a senior vice president of Eisai in June 2015, and to his current position of president of the Oncology Business Group in April 2016. He became CEO of H3 in May 2018.

Mr. Iike received his Master of Business Administration degree from Harvard Business School in 1996. He earned his Bachelor of Science degree in Pharmaceutical Sciences from the University of Tokyo in 1986.

Lihua Yu, Ph.D.

President and Chief Data Science Officer

Lihua Yu, Ph.D.

President and Chief Data Science Officer

Lihua Yu, Ph.D. is President and Chief Data Sciences Officer of H3 Biomedicine. In this role, she is responsible for the overall scientific and business direction of H3. Dr. Yu joined H3 in 2011 and most recently held the position of Chief Data Sciences Officer. An accomplished leader in the biopharmaceutical industry, Dr. Yu has spent more than 17 years in computational biology and bioinformatics and has deep experience in cancer genomics and predictive biomarkers. Her expertise and keen interest in innovatively addressing problems with computational means has enabled her to integrate the bioinformatics discipline into drug discovery and translational science continuums and has been instrumental in developing and advancing H3’s pipeline.

Before coming to H3, Dr. Yu spent 12 years with AstraZeneca’s research and development unit, helping to build and deliver the multinational pharmaceutical company’s oncology bioinformatics capabilities. During her time at AstraZeneca, she provided bioinformatics support to key areas of oncology drug discovery programs, including target identification and patient selection initiatives.

Dr. Yu received a B.E. in biomedical engineering and a B.E. in automation from Tsinghua University in Beijing. She earned a master of engineering from Tsinghua University and a Ph.D. from Boston University. Dr. Yu was a two-time recipient of the AstraZeneca Global Scientific and Technical Achievement Award and is an active member of the American Association for Cancer Research.

Yutaka Ishizaka, J.D.

Chief Operating Officer

Yutaka Ishizaka, J.D.

Chief Operating Officer

Yutaka “Ish” Ishizaka serves as H3 Biomedicine’s Chief Operating Officer and provides leadership in all aspects of the company’s business, including legal, finance, business development, communications and operations. Previously, Ish was Vice President of Eisai Inc.’s largest US-based R&D site in Andover, MA and led business planning, operations and legal affairs. During his tenure, he guided the Andover group’s growth from a mid-sized research laboratory of 50 employees to its peak level of engagement of approximately 300 employees, and also led the development of a new $65 million research facility.

Ish received his J.D. from Columbia University Law School and is a member of the New York and Massachusetts Bar Associations. He earned a B.A. from Trinity College in Hartford, Connecticut.

Dominic Reynolds, Ph.D.

Chemistry

Dominic Reynolds, Ph.D.

Chemistry

Dominic Reynolds, Ph.D., joined H3 Biomedicine in 2011 and has held positions of increasing scientific and management responsibility. Currently, as, Executive Director of Chemistry he leads a team of chemists towards identification and development of novel, small molecule oncology therapeutics. For each project, Dominic and his team of chemists establishes mutually agreeable research plans and timelines, coordinates resources across multiple sites and time zones, mediates and resolves conflicts, and collaborates with internal and external leadership to gain support for critical project needs. Under his leadership, Dominic’s team has delivered a pre-clinical candidate in a highly competitive area of oncology by employing a de-novo design strategy. The molecule is currently undergoing GLP toxicity assessment.

Dominic joined H3 from Forma Therapeutics where in addition to Medicinal Chemistry project leadership he was heavily involved in scientific collaborations targeting over 100,000 novel, stereochemically- complex, small molecules according to the principles of Diversity Oriented Synthesis.

Prior to Forma, Dominic worked at Millennium Pharmaceuticals, Cambridge, MA where he was involved in select oncology research and development projects from lead discovery to candidate delivery for multiple target classes. Dominic also served as a post-doctoral researcher at Glaxo Welcome, UK as well as Harvard University with Professor David Evans; Dominic earned his Ph.D. with Professor Steven Ley, and a B.A. in natural sciences both at the University of Cambridge.

Andrea Gerken, M.B.A.

Business Development

Andrea Gerken, M.B.A.

Business Development

Andrea Gerken leads the Business Development department at H3 Biomedicine, a position she has held since 2012. Under Andrea’s leadership H3 has established an open and collaborative environment which aligns best-in-class scientists and research, with H3’s capabilities and integrates this expertise, insight and resources into novel scientific partnerships. Andreas’s effort has led to the establishment of a host of strategic development partnerships with companies such as Selvita (2013) and Foundation Medicine (2015). Prior to joining H3, Andrea held the position of Manager of Research Operations in Ophthalmology and prior to that as Alliance Manager in the External Drug Discovery group at Novartis Institutes for BioMedical Research (NIBR). At NIBR she was responsible for global alliances which delivered multiple clinical candidates to the NIBR pipeline.

Andrea began her career in industry at Triad Therapeutics and GNF (The Genomics Institute of the Novartis Research Foundation) as a researcher in drug discovery biology. Andrea received her M.B.A. from Columbia Business School and her B.S. degrees in physics and mathematics from the College of Charleston in Charleston, South Carolina.

Aijalon Pyrtel, M.S.

Human Resources

Aijalon Pyrtel, M.S.

Human Resources

Aijalon is an accomplished senior Human Resources professional with 15 years of experience within the biopharmaceutical industry in escalating management roles, supporting executives and managers on strategic and tactical HR issues. In her current position at H3 Biomedicine, she is responsible for leading HR business transformations, building organizational capabilities, and helping to shape the company’s performance culture. Prior to joining H3, Aijalon held the position of Human Resources Director, Oncology Translational Medicine unit of Novartis Pharmaceuticals in Cambridge, MA. Within this capacity Aijalon provided HR guidance to the Leadership team and Business Partner support to global employee population of 400+ associates; while also disseminating advice and coaching on employee relations issues, salary planning, and retention strategies, and leading the performance management, annual compensation planning & employee development processes for this business division. Aijalon also served in senior HR management position at Merck & Co., Inc.; including Change Manager, HR Operations & Integration, Senior Human Resources Business Partner, Merck Research Laboratories, Human Resources Business Partner, HR Leadership Program, and Compensation Analyst, Merck Manufacturing Division, HR Leadership Program.

Aijalon received a Masters of Labor Relations from the University of Illinois and a Bachelor of Science in Psychology from Illinois State University.

Business Development

H3 Biomedicine continues to build and grow its preclinical and clinical portfolio. We are actively engaged in partnering and business development with a goal to advance and build its pipeline through continued collaboration with Eisai as well as with additional partners that can strengthen H3’s ability to quickly deliver novel precision cancer therapies to patients.

H3 is creating novel cancer therapies that will have the potential to impact the disease state and quality of life for those patients who are living with cancer. Our scientists are dedicated to designing a group of best-in-class cancer therapeutics with broad therapeutic potential. In order to accomplish this goal, we are actively seeking partners to advance and expand the H3 pipeline.

H3 has created a culture of “open and innovative collaboration,” which brings together the best scientists, groups and companies and harnesses their expertise, insights and resources through novel working relationships and alliances. In the short time since its inception in 2011, H3 has entered into collaborative relationships with:

In February 2015, Foundation Medicine, Inc. (NASDAQ:FMI) and H3 Biomedicine Inc. announced a multi-year collaboration for the discovery and development of precision medicines in oncology. The collaboration marries Foundation Medicine’s comprehensive genomic knowledgebase of more than 40,000 genomic profiles, FoundationCORE™, with H3 Biomedicine’s drug discovery engine and computational biology platform. The approach aims to identify potential drug targets based on the unique genomic dependencies of individual cancers, rapidly accelerate clinical development, and lead to the commercialization of new, safe and effective precision medicines for individuals living with cancer.
Read Press Release

H3 Biomedicine and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, entered into a strategic collaboration (2013) to validate the importance and druggability of several kinase targets in specific genomic contexts, and to generate multiple novel drug candidates against those targets. Working together, the two companies leverage the strengths of both partners in target validation, precision chemistry, cancer genomics and target biology to advance novel therapies through discovery and in to the clinical setting.
Read Press Release

I am H3

At H3, each team member has a unique role to play in the quest to develop new cancer drugs. Yet we also operate in the spirit of collaboration and camaraderie encouraged by the corporate culture. H3 is made up of dedicated and passionate individuals who recognize that our potential as a team is much greater than if any one of us was working alone.

“My name is Dominic. I am a scientist, a husband, and a father. I whistle, I drink tea, and I synthesize molecules that target cancer.
I am H3.
Read More »
“My name is James. I’m a normal guy with heart-pumping hobbies. I keep H3 Biomedicine’s labs well equipped. For me, there is nothing more exciting than being part of this team.
I am H3.
Read More »
“I am Lihua. I am a computational biologist and an engineer and a mother. I am mathematical, analytical and artistic. I seek patterns that present visually whether in genomics sequencing at work or origami at home with my daughter.
I am H3.
Read More »
“I am Morgan. I practice yoga. I work on balancing work and family. I am calm and ready. And I tried to cure cancer today.
I am H3.
Read More »
“I am Rachel: A scientist who believes in the power of hope. Hope champions our work, and propels us to solve incredibly complex problems. Fluorescent microscopy helps me drive drug discovery, bringing hope to those affected by cancer.
I am H3.
Read More »

In the Community

At H3 Biomedicine, we are fortunate to be part of an extraordinary community that universally incorporates the ethic of giving back. It’s not just a philosophy in words, but all of us at H3 feel compelled to actively participate and support by donating our time and resources. As part of its commitment to social responsibility, H3 stresses the importance of community support by making contributions in a variety of ways. H3’s commitment to supporting community service provides its employees with a unique opportunity to give back to the community where they work. H3 makes a difference through its support of local in and around Greater Boston. Supporting programs like the Pan Mass Challenge, Making Strides, and Light the Night.

Light The Night Walk

Pan-Mass Challenge

Making Strides Against Breast Cancer

Group in pink clothing sponsored by H3
Group of bicyclists in matching green uniforms